Alliqua BioMedical, Inc. (NASDAQ:ALQA) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07
On June26, 2018, Alliqua BioMedical, Inc. (the “Company”) held its 2018 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the following two proposals were submitted to the Company’s stockholders:
Election of five directors to serve on the Company’s board of directors for a term of one year or until their respective successors are elected and qualified, for which the following were nominees: David Johnson, Mark Wagner, Joseph Leone, Gary Restani and Jeffrey Sklar.
|(2)||Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018.|
For more information about the foregoing proposals, see the Company’s definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on May 17, 2018, the relevant portions of which are incorporated herein by reference. Holders of the Company's common stock were entitled to one vote per share of common stock. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below.
|(1)||Election of five directors to serve on the Company’s board of directors for a term of one year or until their respective successors are elected and qualified:|
|(2)||Ratification of the appointment of Marcum LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018:|
The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
About Alliqua BioMedical, Inc. (NASDAQ:ALQA)
Alliqua BioMedical, Inc. is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc. and Choice Therapeutics, Inc. The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds. The Company utilizes hydrogel technology through which hydrogels are manufactured by introducing a hydrophilic polymer into water to create a feed mix. The Company’s commercial wound care portfolio consists of over four product categories, such as Human Biologics; Antimicrobial Protection; Exudate Management and Contract Manufacturing. Human Biologics include BIOVANCE and Extracellular Matrix (ECM). Under Antimicrobial Protection, the Company offers TheraBond 3D Antimicrobial Barrier Systems and SilverSeal.